ACE抑制剂应与血管紧张素受体拮抗剂合用吗？
Should ACE Inhibitors be Combined with Angiotensin II Receptor Antagonists?
我们评价了卒中后早期应用血管紧张素受体拮抗剂，替米沙坦，的作用。
We evaluated the effects of therapy with an angiotensin-receptor blocker, telmisartan, initiated early after a stroke.
对于该患者人群，这种血管紧张素受体拮抗剂还发挥了前所未有的血压控制作用。
The angiotensin receptor blocker also yielded unprecedented blood pressure control for this population of patients.
前言：目的：观察血管紧张素受体拮抗剂缬沙坦对肾病综合征大鼠的干预保护作用。
Objective: to observe the role of Angiotensin II receptor antagonist valsartan on kidney of rat with nephrotic syndrome.
血管紧张素转化酶抑制剂和血管紧张素受体拮抗剂联合用药治疗CKD是否比单药应用要好？
Is Angiotensin-Converting Enzyme Inhibitor and Angiotensin Receptor Blocker Combination therapy Better Than Monotherapy and Safe in Patients With CKD?
目的探讨血管紧张素受体拮抗剂缬沙坦对链脲佐菌素诱导的糖尿病大鼠糖代谢、氧化应激及胰腺病理结构的影响。
Objective to assess the effects of valsartan (an angiotensin receptor blocker, ARB) on glucose metabolism, oxidative stress and pancreatic pathology in streptozotocin-induced diabetic rats.
目的研究血管紧张素转换酶抑制剂(acei)和血管紧张素受体拮抗剂(arb)对2型糖尿病肾病患者肾功能的保护作用。
Objective to investigate the protective effect of angiotensin converting enzyme inhibitor (ACEI) and angiotensin receptor antagonist (ARB) on renal function of type 2 diabetic nephropathy patients.
我们比较了血管紧张素转换酶抑制剂雷米普利、血管紧张素受体拮抗剂替米沙坦以及两药联合对有血管性疾病或高位糖尿病患者的作用。
We compared the ACE inhibitor ramipril, the ARB telmisartan, and the combination of the two drugs in patients with vascular disease or high-risk diabetes.
虽然小剂量的血管紧张素II注射对雄性小鼠血压没有影响，但却能显著减低雌鼠的平均动脉压，而此现象能够被血管紧张素受体拮抗剂PD123319所阻断。
Although this low dose had no effect on MAP in the male, it significantly decreased MAP in the female, and this effect was prevented by coinfusing the animals with PD123319, an antagonist of the AT2R.
但是，对轻中度收缩性HF患者，螺内酯联合血管紧张素ii受体拮抗剂对左室(LV)逆重构的价值目前还不清楚。
However, the value of combining spironolactone with an angiotensin II receptor blocker on LV reverse remodeling in mild-to-moderate systolic HF is unclear.
抗高血压新药非肽类血管紧张素ii受体拮抗剂自二十世纪八十年代发现以来就受到了广泛的关注。
Antihypertensive non-peptide angiotensin II receptor antagonists have been paid much attention since it was found in 1980's.
结果钙拮抗剂、肾上腺素受体阻滞药、血管紧张素转化酶抑制剂(acei)在用药金额、用药频度上分别占前三位。
Results the amount used DDDs of calcium antagonists, adrenergic receptor blockers and ACEI drugs were the head of three.
结果钙拮抗剂、肾上腺素受体阻滞药、血管紧张素转化酶抑制剂(acei)在用药金额、用药频度上分别占前三位。
Results the amount used DDDs of calcium antagonists, adrenergic receptor blockers and ACEI drugs were the head of three.
应用推荐